

REMARKS

In response to the June 10, 2004 Notice to Comply with Sequence Listing Requirements, Applicants submit herewith an initial computer readable form (CFR) copy of the "Sequence Listing"; an initial paper copy of the "Sequence Listing"; a statement that the content of the paper and computer readable copies are the same and include no new matter, in compliance with 37 C.F.R. §§ 1.821-1.825; and replacement figures 12-14 in compliance with 37 C.F.R. §§ 1.84.

The specification has been amended to insert replacement drawings in compliance with 37 C.F.R. §§ 1.84, and to insert the sequence listing.


The Commissioner is hereby authorized to charge any additional fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-0311, Attorney Reference No. 18989-033. Should any questions or issues arise concerning this application, the Examiner is encouraged to contact the undersigned at the telephone number provided below.

Respectfully submitted,



Ingrid A. Beattie, Reg. No.42,306
Cynthia A. Kozakiewicz, Reg. No.42,764
MINTZ, LEVIN, COHN, FERRIS,
GLOVSKY and POPEO, P.C.
One Financial Center
Boston, Massachusetts 02111
Tel: (617) 542-6000
Fax: (617) 542-2241
Customer No. 30623

Dated: October 7, 2004



		Section 1					
	(1)	1	10	20	30	40	52
ApoB 1-269	(1)	-----MDPPRPALLALLA[P]LLLLLLAGAR[EE]LE					
CD1d human	(1)	MGCLLFLLWALLQAWGSAEVPQRLFPLRCLQ[S]FANSSWTRTD[LAW]GE					

		Section 2					
	(53)	53	60	70	80	90	104
ApoB 1-269	(34)	NV	LVC PKD	TRF	HL	K	YN-----YEAE--S-SSGVPGTA[SRS
CD1d human	(53)	LQ	HSWSND	DTV	SL	P	QGTFS DQQWETLQHIFRVYRSSFTRDVK[FAK

		Section 3					
	(105)	105	110	120	130	140	156
ApoB 1-269	(73)	ATR	NCK	ELEV PQLCSFILK--	S	-----QCTLKEVYGFNP	
CD1d human	(105)	MLR	SYP	ELQVSAGCEVHPGNA	NNFFHVA	FQ GK DILSFQGT	SWEPTQEAP

		Section 4					
	(157)	157	170	180	190	208	
ApoB 1-269	(108)	EGKALLKKT KNS	E	AAAMSR	ELKLAIPEGKQVFLYPEKDEPTYILN	IKRG	
CD1d human	(157)	LWVNLAIQVLNQ	K	TRETVQ	LLNGTC PQFVSGLL	ESGKSE-----LKKQV	

		Section 5					
	(209)	209	220	230	240	250	260
ApoB 1-269	(160)	IISALLVPPE	EEAKQ	LF	DTVYGNCS THFTVKTR	GN-----	A-
CD1d human	(204)	KPKAWLSRGP	PGPGR	LL	CHVSGFY PKPVWVKWM	GEQEQQGTQPGD	LP

		Section 6					
	(261)	261	270	280	290	300	312
ApoB 1-269	(201)	-----T-----	STERDLGQCDR FKP IRTGISP		ALIKGM	RPLSTLI	S
CD1d human	(256)	NADETWYLRATL	VAGEAAGLSCR VKHSSLEGQD		VLYWGG	YTSMGLI	L

		Section 7			
	(313)	313	320	330	343
ApoB 1-269	(242)	QS-----CQ	TLDAKRKHVAE	CKEQ	
CD1d human	(308)	VLACLLFLLIVG	TSRFRKQTSYQ	L---	

SEG ID NO: 11
SEG ID NO: 12

Fig. 12



		Section 1									
		(1) 1	10	20	30	40	52				
ApoB 512-721	(1)	-----K									
CD1d human	(1)	MGCLLFLLLWALLQAWGSAEVPQRLFPLRCLQISSFANSSWTRTDGLAWLGE									
		Section 2									
		(53) 53	60	70	80	90	104				
ApoB 512-721	(2)	CVQS	KPSLMIQKA	QALRKMEPKDKDQEVLLQTFLDDASPGD	R	AA	LM				
CD1d human	(53)	LQTH	WSNDSDTVR	KPWSQGTFS	DQWETLQHI	FRVYRSSFT	DKEAK				
		Section 3									
		(105) 105	110	120	130	140	156				
ApoB 512-721	(54)	RS--PSQAD	NKIVQ	LPWEQNE	-----QVKN		VAHIAN				
CD1d human	(105)	RLSYPLELQ	SAGCE	HPGNASNNFFHVA	FQ	GKDILSFQ	GTSEPQEAP				
		Section 4									
		(157) 157	170	180	190	208					
ApoB 512-721	(89)	LNSEE	D	QDLKKLV	EA	KESQLPTVMDFRKFSRN	-----YQLYKSVL				
CD1d human	(157)	WVNLA	Q	LNQDKWT	ET	QWLLNGT	CPQFVSGLLESGKSELKKQVKPKW				
		Section 5									
		(209) 209	220	230	240	250	260				
ApoB 512-721	(135)	PSLDP	S	KIEGNL	FDPNN	LPK---ESM	TTLTA	FGFAS	D	EI	LEG
CD1d human	(209)	LSRGP	P	PGRLLL	CHVSG	YPKPVVVKW	GEQE	QQTQP	D	PN	DET
		Section 6									
		(261) 261	270	280	290	300	312				
ApoB 512-721	(184)	KGFEPTL	A	FGKQ	-----FFP		SVNKALYW	-----			
CD1d human	(261)	WYLRATL	V	AGEA	GLSCR	VKHSSL	GQDIV	LYW	GGSYT	SMGLIALAVLAC	
		Section 7									
		(313) 313	320	335							
ApoB 512-721	(211)	-----									
CD1d human	(313)	LLFLLIVGFTSRFRQTSYQGV									

SEQ ID NO: 13

SEQ ID NO: 15

SEQ ID NO: 13
SEQ ID NO: 15

Fig. 13



		Section 1							
		(1)	1	10	20	30	40	52	
ApoB 270-570	(1)	-----	FSYNNKYGMVAQVTQTLKLEDTPKINSRFFGEGT	KMGLA	EST				
CD1d human	(1)		MGCLLFLLLWALLQAWGSAEVPQRLFPLRCLQISSFANSSWT	TDGLA	LGE				
		Section 2							
		(53)	53	60	70	80	90	104	
ApoB 270-570	(45)		KSTSPPK	AEAV	LQELKKLTIS	Q	IQRA	LPN	VTEL RGLSDEAVTS
CD1d human	(53)		LQTHSWS	DSDT	LKPWSQGTFS	Q	WETL	HIF	YRSSFTRDVKEFAK
		Section 3							
		(105)	105	110	120	130	140	156	
ApoB 270-570	(97)		LPQLIE	SSP	LQALVQCG	PQCSTHI	Q	LK	VHANPLLIDVVTYLVAL
CD1d human	(105)		LRLSYP	ELQ	AGCEVHPG	ASNNFFH	A	QG	DILSFQGT SWEPTQEAP
		Section 4							
		(157)	157	170	180	190	208		
ApoB 270-570	(149)		PEPSAQQ	REIFNMAR	QRSRATLYALSHAVNNYHK	NP	GTQEL	DIAN	
CD1d human	(157)		WVNLAIQ	LNQDKWTR	TVQWLLNGT	CPQFVSGLLE	GK	ELKKQ	KPKA
		Section 5							
		(209)	209	220	230	240	250	260	
ApoB 270-570	(201)		LMEQIQDD	-----C	GDEDYTYL	LR	IGNMGQTMEQLTPELKS	ILK	
CD1d human	(209)		LSRGPSPGPGRLLLVCHV	GFYPKPVW	KW	RGEQEQQGTQPGDILPN	DET		
		Section 6							
		(261)	261	270	280	290	300	312	
ApoB 270-570	(244)		CVQSTKPS	IQKAAIQ	LRKMEPKDKDQ		LQTFLDDASPGDKRLAAYLM		
CD1d human	(261)		WYLRATLD	AGEAAGL	CRVKHSSLEGQ		LYWGGSYTSMGLIALAVLAC		
		Section 7							
		(313)	313	320	335				
ApoB 270-570	(296)		L	RSPS	-----				
CD1d human	(313)		L	FLLIVGFTSRFKRQTSYQGV	L				

SEQ ID NO: 14

SEQ ID NO: 15

SEQ ID NO: 14
SEQ ID NO: 16

Fig. 14